Background
==========

The EuroCMR registry determined indications, image quality, safety and impact on patient management of clinical routine CMR in a multi-national European setting.

Furthermore, interim analyses of two specific protocols evaluating the prognostic potential of CMR in patients with coronary artery disease (CAD) and hypertrophic cardiomyopathy (HCM) are presented.

Methods
=======

Multi-center registry with consecutive enrollment of patients in 57 centers in 15 countries \[[@B1]\].

Results
=======

27,781 patients were enrolled. The most frequent indications were risk stratification in CAD/ischemia (34.2%), workup of cardiomyopathies (32.2%) and assessment of viability (14.6%). Image quality was diagnostic in 98%. Severe complications were rare (0.03%).

In 61.8% CMR findings had an impact on patient management. In 8.7% the final diagnosis changed based on CMR findings (Table [1](#T1){ref-type="table"}).

###### 

Impact of CMR on patient management by indication

                                                                                Myocarditis/ Cardiomyopathy   Suspected CAD/Ischemia   Viability
  ----------------------------------------------------------------------------- ----------------------------- ------------------------ -----------
  All (from n = 27781)                                                          32.2%                         34.2%                    14.6%
  New diagnosis                                                                 11.4%                         8.1%                     5.3%
  Therapeutic consequences:                                                                                                            
  Change in medication                                                          25.3%                         24.3%                    33.2%
  Invasive procedure                                                            6.9%                          23.1%                    24.2%
  Hospital discharge                                                            10.4%                         14.3%                    6.9%
  Impact on patient management (new diagnosis and/or therapeutic consequence)   55.1%                         71.4%                    71.5%

Kaplan-Meier survival curves of the interim analyses showed low adverse event rates in patients with suspected CAD with a normal stress CMR (1.0% per year), and in HCM without delayed enhancement (2.7% per year).

Conclusions
===========

The most important CMR indications in Europe are risk stratification in suspected CAD/ischemia, work-up of cardiomyopathies and assessment of viability. CMR is a safe procedure, has diagnostic image quality in more than 98% of cases, and its results have a strong impact on patient management. Interim analyses underscore the prognostic value of clinical routine CMR in patients with CAD and HCM.

Funding
=======

Medtronic Inc., Minneapolis MN, USA.

Novartis International AG, Basel, Switzerland.

Siemens Health Care, Erlangen, Germany.
